-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Today, PathAI and GlaxoSmithKline (GSK) jointly announced a multi-year strategic R&D collaboration that will leverage PathAI’s digital pathology technology platform (including its AIM-NASH tool) to accelerate oncology and Scientific research and drug development programs for nonalcoholic steatohepatitis (NASH)
.
PathAI is one of Fierce Medtech's annual Medical Technology "Fighting Companies" (Fierce 15) whose goal is to use artificial intelligence and deep learning to analyze pathology data to facilitate the development of innovative diagnostics and therapies
.
For example, the company's AI-based nonalcoholic steatohepatitis (NASH) scoring system can accurately reproduce the clinical research endpoint of NASH symptom clearance
.
An AI-driven PD-L1 score was able to identify 28% of PD-L1-positive patients among manually assessed PD-L1-negative patients in a clinical trial
.
The company closed a $165 million Series C round last year
.
"We look forward to leveraging PathAI's expertise and models to advance the development of GSK's unique AI models, with a focus on designing better models that lead to improved treatment options for cancer and NASH patients
.
" Kim, Global Head of Artificial Intelligence and Machine Learning at GSK Dr.
Branson said
.
"This collaboration brings together GSK and PathAI's platform engineering teams to jointly develop algorithms to rapidly integrate insights into clinical trials," said PathAI co-founder and CEO Dr.
Andrew Beck.
"Through this collaboration, we aim to is harnessing the power of machine learning to predict which patients with high needs will benefit from therapy
.
"Reference: [1] PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development.
Retrieved April 5, 2022, from https:// -GlaxoSmithKline-Sign-Multi-Year-Agreement-to-Accelerate-Research-and-Drug-Development Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the opinions in this article do not It represents the position of WuXi AppTec, nor does it mean that WuXi PharmaTech supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
For guidance on treatment plans, please go to a regular hospital for treatment
.
